Biogen Inc
BIIB181.940USD
-0.020-0.01%
Handelsschluss 11/26, 16:00（ET）Kurse um 15 Minuten verzögert
26.69BMarktkapitalisierung
16.59KGV TTM
mehr Informationen über Biogen Inc Unternehmen
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Biogen Inc Informationen
BörsenkürzelBIIB
Name des UnternehmensBiogen Inc
IPO-datumSep 17, 1991
CEOMr. Christopher A. (Chris) Viehbacher
Anzahl der mitarbeiter7605
WertpapierartOrdinary Share
GeschäftsjahresendeSep 17
Addresse225 Binney Street
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142
Telefon17814642000
Websitehttps://www.biogen.com/
BörsenkürzelBIIB
IPO-datumSep 17, 1991
CEOMr. Christopher A. (Chris) Viehbacher
Führungskräfte von Biogen Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.42K
+39.19%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
5.77K
-8.22%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
5.47K
+76.33%
Ms. Susan Langer
Ms. Susan Langer
Independent Director
Independent Director
3.79K
+166.90%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
Andere
498.00M
18.82%
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.38B
52.21%
Rest of World
937.60M
35.44%
United states-Revenues from anti-CD20 therapeutic
467.30M
17.66%
Rest of World-Other revenues
244.60M
9.25%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
Andere
498.00M
18.82%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
Andere
64.59%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
Andere
64.59%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
52.44%
Investment Advisor/Hedge Fund
26.19%
Hedge Fund
8.03%
Pension Fund
2.94%
Research Firm
2.45%
Sovereign Wealth Fund
1.59%
Bank and Trust
1.59%
Individual Investor
0.17%
Family Office
0.15%
Andere
4.45%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
2020
136.90M
93.32%
-6.47M
2025Q2
2075
135.74M
92.58%
-12.69M
2025Q1
2149
136.82M
93.38%
-11.44M
2024Q4
2130
138.58M
94.69%
-5.19M
2024Q3
2109
135.95M
93.33%
-6.54M
2024Q2
2116
135.72M
93.21%
-7.14M
2024Q1
2121
136.44M
93.87%
-5.95M
2023Q4
2151
135.61M
93.59%
-2.07M
2023Q3
2177
132.42M
91.43%
-7.53M
2023Q2
2240
133.77M
92.42%
-4.86M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
17.21M
11.74%
+255.44K
+1.51%
Jun 30, 2025
PRIMECAP Management Company
15.80M
10.78%
-141.14K
-0.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.19M
5.59%
-504.36K
-5.80%
Jun 30, 2025
State Street Investment Management (US)
7.47M
5.09%
+71.90K
+0.97%
Jun 30, 2025
Wellington Management Company, LLP
4.80M
3.27%
+125.98K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.92M
2.67%
+71.29K
+1.85%
Jun 30, 2025
Point72 Asset Management, L.P.
3.83M
2.61%
+3.42M
+840.86%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
3.00M
2.05%
-10.62K
-0.35%
Aug 31, 2025
Norges Bank Investment Management (NBIM)
2.26M
1.54%
-61.02K
-2.62%
Jun 30, 2025
Invesco Capital Management LLC
2.04M
1.39%
+32.06K
+1.59%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
Invesco Biotechnology & Genome ETF
5.03%
iShares Neuroscience and Healthcare ETF
4.13%
First Trust NASDAQ Pharmaceuticals ETF
3.82%
VanEck Biotech ETF
3.33%
First Trust NYSE Arca Biotechnology Index Fund
3.24%
Invesco Pharmaceuticals ETF
2.74%
First Trust Health Care Alphadex Fund
2.36%
Global X US Cash Flow Kings 100 ETF
2.26%
ProShares Ultra Nasdaq Biotechnology
2.12%
Invesco Nasdaq Biotechnology ETF
2.08%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil5.03%
iShares Neuroscience and Healthcare ETF
Anteil4.13%
First Trust NASDAQ Pharmaceuticals ETF
Anteil3.82%
VanEck Biotech ETF
Anteil3.33%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.24%
Invesco Pharmaceuticals ETF
Anteil2.74%
First Trust Health Care Alphadex Fund
Anteil2.36%
Global X US Cash Flow Kings 100 ETF
Anteil2.26%
ProShares Ultra Nasdaq Biotechnology
Anteil2.12%
Invesco Nasdaq Biotechnology ETF
Anteil2.08%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Biogen Inc?
Die fünf größten Anteilseigner von Biogen Inc sind:
The Vanguard Group, Inc. hält 17.21M Aktien, was 11.74% der Gesamtaktien entspricht.
PRIMECAP Management Company hält 15.80M Aktien, was 10.78% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 8.19M Aktien, was 5.59% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 7.47M Aktien, was 5.09% der Gesamtaktien entspricht.
Wellington Management Company, LLP hält 4.80M Aktien, was 3.27% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 17.21M Aktien, was 11.74% der Gesamtaktien entspricht.
PRIMECAP Management Company hält 15.80M Aktien, was 10.78% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 8.19M Aktien, was 5.59% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 7.47M Aktien, was 5.09% der Gesamtaktien entspricht.
Wellington Management Company, LLP hält 4.80M Aktien, was 3.27% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Biogen Inc?
Die drei wichtigsten Anteilseigner-Typen von Biogen Inc sind:
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
Wie viele Institutionen halten Anteile an Biogen Inc (BIIB)?
Mit Stand vom 2025Q3 halten 2020 Institutionen Anteile an Biogen Inc, mit einem Gesamtmarktwert von etwa 136.90M, was 93.32% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um 0.73% gestiegen.
Was ist die größte Einnahmequelle von Biogen Inc?
Am FY2025Q2 erzielte das Geschäft mit MS product revenues-TYSABRI für Biogen Inc den höchsten Umsatz in Höhe von 839.80M, was 31.74% des Gesamtumsatzes entspricht.
